Summit Therapeutics is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of medicinal therapies intended to improve quality of life and resolve serious unmet medical needs, self-described.

Summit Therapeutics

IPv6

Director, Statistical Programmer

Amulya Bista

Healthcare

Chien-Ming Li

Risk, Safety, Compliance

Chris Fazio

Engineering

Clive Bathurst

Senior Patent Counsel/Head of Intellectual Property

David Carpenter

Senior Director of GMP Quality Assurance

Edward Hazelrig

Finance and Administration

Erin Heighton

Business Management

Hugh (Zhengyuan) Wang

Marketing and Product

Jianling Li

Executive Scientific Director, Clinical Development

Joi Ninomoto

Manmeet S. Soni

Ankur Dhingra

Chief Financial Officer

Laura Chow

Senior Vice President Clinical Development

Nawaz Khan

VP Anti-infectives Research

Chief Operating Officer

Maky Zanganeh

Robert W. Duggan

Chief Executive Officer

Dave Gancarz

Vice President, Investor Relations & Corporate Strategy

Dame Kay Davies

Co-founder

Medical Device Female Founded Companies

Therapeutics Public Companies

United Kingdom Companies With More Than 10 Employees (Top 10K)

Health Care Companies (Top 10K)

Summit Therapeutics is a clinical-stage drug discovery and development company. The company's new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers.

Post-IPO Equity - Summit Therapeutics

CARB-X

Grant - Summit Therapeutics

Eurofarma

Biomedical Advanced Research and Development Authority (BARDA)

Abingdon

Oxfordshire

United Kingdom

Europe

Summit Therapeutics to Present at

Summit Therapeutics to Present at Upcoming Investor Conferences

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Is Summit Therapeutics a Millionaire Maker?

Could Summit Therapeutics Become the Next Merck?

Summit Therapeutics completes enrollment in Phase III HARMONi trial

Where Will Summit Therapeutics Be in 3 Years?

Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics

Summit Therapeutics just downgraded at Citi, here's why

A bispecific antibody combining immunotherapy via PD-1 blockade with anti-angiogenesis effects by blocking VEGF, currently in Phase III clinical trials for non-small cell lung cancer.

A clinical trial initiative by Summit Therapeutics to evaluate the efficacy and safety of their investigational therapies.

A specific Phase III clinical trial under the HARMONi initiative, focusing on the treatment of non-small cell lung cancer with ivonescimab.

A program that allows patients with serious or life-threatening conditions to access investigational therapies outside of clinical trials.

United States

North America

Chile

South America

India

Asia

HTML5

Gravity Forms

Wordpress

Modernizr

F5 NGINX

DigiCert

GoDaddy Premium DNS

Google Maps API

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 15, 2024 3:09 PM	a0deb6fb
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 15, 2024 3:09 PM	c009f6fb
crunchbase trigger	general	Nov 27, 2024 12:50 PM	469dcce1
crunchbase profile	general	Nov 27, 2024 6:12 PM	5648d0b4
li profile	general
translate crunchbase fundingrounds	general	Nov 27, 2024 7:33 PM	d65459d6
peers	general	Oct 15, 2024 3:09 PM	f9befc92
news basic	general	Oct 15, 2024 3:09 PM	f63f12aa
bundesanzeiger	filings
financials download nd	financials
private financials	financials

SUMM

COM:SUMMITTHERAPEUTICS

Summit Therapeutics